MediciNova to Present at the LD Micro Main Event XIX Investor Conference

Core Viewpoint - MediciNova, Inc. is actively engaging with investors by presenting a corporate overview at the LD Micro Main Event XIX Investor Conference, highlighting its ongoing clinical developments and future prospects [1][2]. Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [3]. - The company has a late-stage pipeline that includes 11 clinical programs, primarily centered around two compounds: MN-166 (ibudilast) and MN-001 (tipelukast) [3]. - MN-166 is currently in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is ready for Phase 3 for progressive multiple sclerosis (MS) [3]. - MN-166 is also being evaluated in Phase 2 trials for Long COVID and substance dependence [3]. - MN-001 has been evaluated in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and is currently undergoing a second Phase 2 trial for non-alcoholic fatty liver disease (NAFLD) [3]. Conference Details - The presentation at the LD Micro Main Event XIX is scheduled for October 20, 2025, at 1:30 PM Pacific Time [2]. - A live webcast of the presentation will be available on the investor relations section of the MediciNova website, with a replay accessible for 90 days post-event [2]. - Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference, providing opportunities for direct engagement with investors [2].